ANI Pharmaceuticals News and Activities
Presence
ANI Pharmaceuticals specializes in the development, manufacturing, and marketing of branded and generic prescription pharmaceuticals, focusing on market needs and niche opportunities in the healthcare sector. Their target customers include healthcare providers, clinics, and hospitals across various therapeutic areas.
- Branded pharmaceuticals
- Generic pharmaceuticals
- Contract manufacturing
2024 Revenue: Expected to reach around $500 million
Employees: 200
ANI Pharmaceuticals is one of the...
ANI Pharmaceuticals is a company listed under the stock ticker ANIP (US).
ANI Pharmaceuticals has a direct presence in 2 countries.
They are in:
- Biotechnology50%
- Pharmaceuticals50%
Acquisition, funding and merger involving ANI Pharmaceuticals.
- ANI Pharmaceuticals has acquired Alimera Sciences (posted on September 16 2024).
- ANI Pharmaceuticals has announced the acquisition of Alimera Sciences (posted on June 26 2024).
Executives
View the org chart displaying its 25 main executives
Most searched biographies at ANI Pharmaceuticals
- Nikhil Lalwani, Director, President and Chief Executive Officer
- Antonio Pera, Director
- Thomas Haughey, Director
Create your alert
to follow the executive moves at ANI Pharmaceuticals.
Biotechnology
ANI Pharmaceuticals has 2,338 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Biogen (United States (USA)).
Popular M&A news in Biotechnology
- Jade Biosciences and Aerovate Therapeutics have announced they will merge (posted on April 30 2025)..
- Deepull has just announced a $50 Million fundraising (posted on April 29 2025).
- Biolinq has just announced a $100 Million fundraising (posted on April 23 2025).
Popular contacts in Biotechnology
News
Press releases by ANI Pharmaceuticals
- ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Clorazepate Dipotassium Tablets USP
- ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients
- ANI Pharmaceuticals Announces Consolidation of Manufacturing Network, Capturing Operational Synergies Post Novitium Acquisition
- ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP
- ANI Pharmaceuticals to Present at Upcoming Healthcare Investor Conferences
- ANI Pharmaceuticals Reports First Quarter 2022 Results; Provides Purified Cortrophin® Gel Net Revenue Guidance and Full-Year 2022 Total Company Net Revenue Guidance of $295 Million to $315 Million
- ANI Pharmaceuticals to Discuss First Quarter 2022 Financial Results on May 10, 2022
- ANI Pharmaceuticals Announces the Launch of Misoprostol Tablets
- ANI Pharmaceuticals Appoints Experienced Commercial Leader, Renee P. Tannenbaum, Pharm.D., MBA, to Board of Directors
- ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; Strong Foundation in Place to Drive Sustainable Growth
- View more press releases Close
Social media about ANI Pharmaceuticals
- ANI Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- ANI Pharmaceuticals on LinkedIn, Twitter & YouTube
